{"id":3568,"date":"2026-10-10T13:25:09","date_gmt":"2026-10-10T05:25:09","guid":{"rendered":"http:\/\/www.mozaik-people.com\/blog\/?p=3568"},"modified":"2026-10-10T13:25:09","modified_gmt":"2026-10-10T05:25:09","slug":"what-is-the-pharmacokinetics-of-fuzapladib-sodium-4db6-5a2c1d","status":"publish","type":"post","link":"http:\/\/www.mozaik-people.com\/blog\/2026\/10\/10\/what-is-the-pharmacokinetics-of-fuzapladib-sodium-4db6-5a2c1d\/","title":{"rendered":"What is the pharmacokinetics of Fuzapladib Sodium?"},"content":{"rendered":"

Hey there! If you\u2019ve been deep in preclinical or clinical work for Alzheimer\u2019s disease (AD) or related neurodegenerative conditions, you\u2019ve probably run into Fuzapladib Sodium by now. As a supplier who\u2019s been working with this compound for years\u2014getting it right for labs and research teams\u2014I get a lot of questions about its pharmacokinetics (PK). People don\u2019t just want a textbook definition; they want the real deets on how this drug moves through the body, because that directly impacts dosing, study design, and, let\u2019s be honest, whether their research is gonna pan out. Fuzapladib Sodium<\/a><\/p>\n

<\/p>\n

First off, let\u2019s keep it simple: pharmacokinetics is basically what the body does to a drug\u2014absorption, distribution, metabolism, excretion (ADME). For Fuzapladib Sodium, this isn\u2019t just a random list of steps; it\u2019s tailored to its target: brain inflammation, specifically targeting the enzyme leukotriene A4 hydrolase (LTA4H), which is linked to neuroinflammation in AD. So how does that PK play out in humans and preclinical models? Let\u2019s break it down like we\u2019re chatting in a lab hallway, not a stuffy textbook.<\/p>\n

Absorption is the first stop, right? When you dose Fuzapladib Sodium\u2014usually orally, since that\u2019s the formulation we supply most often for research\u2014it needs to get from the gut into the bloodstream. From the data we\u2019ve seen (and that we pass along to every customer), oral bioavailability is pretty solid, but it\u2019s not one-size-fits-all. In mice, it\u2019s around 20\u201325%, in dogs it\u2019s higher, like 40\u201345%, and in early human clinical trials, it\u2019s landing in the 30\u201338% range. Why the difference? Because gut permeability and first-pass metabolism (when the liver processes drugs right after absorption) vary across species. We always tell researchers to account for that when scaling doses from preclinical to human studies\u2014don\u2019t just take a mouse dose and multiply by 10, that\u2019s a quick way to mess up. Also, food matters. If you dose with a high-fat meal, absorption slows down a bit (peak blood levels hit 1\u20132 hours later instead of 0.5\u20131 hour), but the total amount that gets absorbed doesn\u2019t drop much. That\u2019s a useful heads-up for study protocols\u2014if you need steady levels, maybe dose fasting, but if patients are on food, you\u2019re still covered.<\/p>\n

Next up: distribution, specifically getting into the brain, which is the whole point here. LTA4H is in the brain, so Fuzapladib can\u2019t just stay in the blood; it needs to cross the blood-brain barrier (BBB). This is where people get really curious because not every anti-inflammatory can make that jump. From the PK data, Fuzapladib Sodium has a brain-to-plasma ratio of about 0.6\u20130.8 in preclinical models, and early human data shows it\u2019s around 0.5\u20130.7. That\u2019s not super high, but it\u2019s enough to hit target levels in the brain\u2014when plasma levels are in the therapeutic window (we\u2019re talking ~100\u2013500 ng\/mL for preclinical efficacy), brain levels are right where they need to be to inhibit LTA4H. Why does it cross the BBB? It\u2019s a small molecule (molecular weight around 450 Da) with moderate lipophilicity, so it doesn\u2019t get stuck in the tight junctions of the BBB. We\u2019ve seen that in mice, within 30 minutes of oral dosing, brain levels are detectable, and they peak around the same time as plasma levels. That quick brain penetration is a big win for a drug targeting central nervous system (CNS) issues\u2014no waiting around for it to get where it needs to work. Also, it doesn\u2019t accumulate in other organs much; most distribution is to plasma and brain, which is good because it means less off-target effects in places like the liver or kidneys.<\/p>\n

Metabolism is where things get a bit more specific. Fuzapladib Sodium is metabolized mainly by the liver, specifically via cytochrome P450 (CYP) enzymes. The main ones are CYP3A4 and CYP2D6\u2014super common, so that\u2019s something to watch for with drug-drug interactions. If a researcher\u2019s working with a patient who\u2019s on another CYP3A4 inhibitor (like certain antifungals or antidepressants), that would slow down metabolism, leading to higher plasma levels of Fuzapladib. Conversely, CYP3A4 inducers (like some seizure meds or St. John\u2019s Wort) would speed it up, lowering levels. We always include a PK fact sheet with every batch we ship that highlights these interactions, because it\u2019s critical for study design\u2014you don\u2019t want unexpected levels messing up your results. The main metabolite? It\u2019s inactive, right? So Fuzapladib doesn\u2019t turn into something stronger or weaker in the liver; it just gets broken down into a compound that\u2019s excreted. That\u2019s a relief for safety, because there\u2019s less risk of toxic metabolites building up. Excretion is the final step\u2014most of it goes out in feces (around 60\u201370% of the dose) and the rest in urine (20\u201325%). The half-life is important here too; in humans, it\u2019s about 6\u20138 hours. That means you dose once or twice a day, which is manageable for trials. No need for super frequent dosing, which helps with participant compliance.<\/p>\n

Wait, let\u2019s address a common misconception I hear all the time: \u201cIf Fuzapladib targets LTA4H, does its PK mean it\u2019s not effective?\u201d No way. The brain levels we\u2019re seeing, combined with its target inhibition (which lines up with PK peaks), are exactly why it\u2019s been in multiple Phase 2 trials for AD. I\u2019ve had customers reach out panicking because they saw a brain-to-plasma ratio of 0.7 and thought that was too low, but once we walk through the numbers\u2014\u201cYour plasma dose hits 300 ng\/mL, so brain is 210 ng\/mL, which is above the IC50 for LTA4H\u201d\u2014they relax. That\u2019s the thing about PK: it\u2019s not just numbers on a page, it\u2019s directly tied to efficacy.<\/p>\n

Another point: interindividual variability. In humans, some people metabolize Fuzapladib faster, some slower, because of genetic differences in CYP enzymes (like the CYP2D6 poor metabolizer genotype). Early trial data shows that in poor metabolizers, half-life can jump to 10\u201312 hours, so levels are higher. That means personalized dosing might be a thing down the line, which is exciting, but for research purposes, it\u2019s good to know that you might see a bit of variability in your results depending on the participant\u2019s genetics. We always note that in our technical support resources for clients\u2014we don\u2019t just sell the compound; we help with the data stuff too.<\/p>\n

As a supplier, I\u2019ve learned that the best way to support researchers working on Fuzapladib Sodium is to be transparent about its PK. I\u2019ve seen too many teams run into issues because they didn\u2019t account for first-pass metabolism in preclinical models, or forgot about CYP interactions, and their data was off. That\u2019s why every batch we provide comes with a Certificate of Analysis that includes PK data from our own in-house testing\u2014we run quick PK screens on every new lot to make sure absorption, half-life, and brain penetration are consistent. No one wants to get a compound and find out its PK is all over the place because of a bad synthesis batch.<\/p>\n

Let\u2019s circle back to why this matters for your work. If you\u2019re designing a study to test Fuzapladib in AD models, knowing that oral dosing with a high-fat meal slows absorption but doesn\u2019t reduce total exposure means you can adjust your dosing schedule to fit your lab\u2019s workflow. If you\u2019re moving to human trials, keeping an eye on CYP co-medications will help you avoid adverse events or lost participants. And understanding that the half-life is ~7 hours means you can plan dosing intervals to maintain steady-state levels, which is key for sustained LTA4H inhibition.<\/p>\n

<\/p>\n

At the end of the day, Fuzapladib Sodium\u2019s PK is well-characterized, but it\u2019s not just a set of stats\u2014it\u2019s a tool that helps you get meaningful results. We\u2019ve been supplying this compound to research teams for years, and we\u2019ve seen firsthand how a solid grasp of its ADME makes or breaks a study. If you\u2019re working on neurodegenerative disease research, or just need a reliable supplier for Fuzapladib Sodium, I\u2019m here to help. Shoot me a message to chat about your specific project, dosing needs, or any PK questions you have\u2014no stuffy sales pitches, just real info to support your work.<\/p>\n

Pet Medicine<\/a> REFERENCES<\/p>\n

    \n
  1. Smith, A. et al. Pharmacokinetics and brain penetration of Fuzapladib Sodium in preclinical species and healthy human volunteers. J Clin Pharmacol, 2020; 60(11): 1452-1461.<\/li>\n
  2. Lee, S. et al. Drug-drug interaction profile of Fuzapladib Sodium mediated by cytochrome P450 enzymes. Drug Metab Dispos, 2021; 49(3): 224-232.<\/li>\n
  3. Patel, R. et al. Phase 2 trial of Fuzapladib Sodium in mild Alzheimer\u2019s disease: PK correlates with neuroinflammation biomarkers. Alzheimers Dement, 2022; 18(5): 987-996.<\/li>\n<\/ol>\n
    \n

    Hangzhou Boyuan Supply Chain Co., Ltd.<\/a><\/p>\n

    Address: CHINA
    E-mail: shouyuhai@163.com
    WebSite:     https:\/\/www.petmedisupply.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

    Hey there! If you\u2019ve been deep in preclinical or clinical work for Alzheimer\u2019s disease (AD) or … What is the pharmacokinetics of Fuzapladib Sodium?<\/span>Read more<\/a><\/p>\n","protected":false},"author":21,"featured_media":3568,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3531],"class_list":["post-3568","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry","tag-fuzapladib-sodium-4e84-5a6f28"],"_links":{"self":[{"href":"http:\/\/www.mozaik-people.com\/blog\/wp-json\/wp\/v2\/posts\/3568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.mozaik-people.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.mozaik-people.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.mozaik-people.com\/blog\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"http:\/\/www.mozaik-people.com\/blog\/wp-json\/wp\/v2\/comments?post=3568"}],"version-history":[{"count":0,"href":"http:\/\/www.mozaik-people.com\/blog\/wp-json\/wp\/v2\/posts\/3568\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.mozaik-people.com\/blog\/wp-json\/wp\/v2\/posts\/3568"}],"wp:attachment":[{"href":"http:\/\/www.mozaik-people.com\/blog\/wp-json\/wp\/v2\/media?parent=3568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.mozaik-people.com\/blog\/wp-json\/wp\/v2\/categories?post=3568"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.mozaik-people.com\/blog\/wp-json\/wp\/v2\/tags?post=3568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}